<DOC>
<DOCNO>1070119_business_story_7281969.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 Ranbaxy in fine form

 OUR BUREAU

 Malvinder (extreme right) : Good show

 Jan. 18: Increased sales in the US and healthy domestic growth spurred Ranbaxy Laboratorys fourth-quarter net profit by 167 per cent to Rs 185.9 crore compared with Rs 69.6 crore in the corresponding quarter of the previous fiscal.

 The companys consolidated sales in the quarter grew 22 per cent at Rs 1,707.7 crore against Rs 1,405.5 crore in the year-ago quarter.

 Well monitored expenses helped the company post good growth in the quarter and the fiscal 2006. We have also had a gain in terms of productivity in the year, Ranbaxy CEO and managing director Malvinder Mohan Singh said.

 For the year ended December 31, Ranbaxys net profit grew 97 per cent at Rs 520.4 crore compared with Rs 264.2 crore previous year.

 The consolidated sales during the year stood at Rs 6,069.8 crore against Rs 5,188 crore a year ago.

 Nicholas Piramal

 Nicholas Piramal India Ltd (NPIL) has posted a 82 per cent rise in net profit on a stand-alone basis at Rs 43.3 crore for the quarter ended December 31, 2006 compared with Rs 23.7 crore in the same period last year. This robust performance was triggered by a 14.3 per cent growth in its topline that saw net sales at Rs 408.03 crore compared with Rs 356.89 crore in the corresponding period last fiscal. 

 Total operating income on a consolidated basis for the quarter was up by 60 per cent to Rs 650 crore. Operating profit increased by 185.3 per cent to Rs 97.04 crore and net profit for the quarter was up by 473.9 per cent to Rs 55.55 crore. 




</TEXT>
</DOC>